(BOSTON) – Jay Teich, former Seahorse Bioscience CEO, will receive the first ever CEO Innovator Award from the Society for Redox Biology and Medicine (SFRBM). This international award will annually recognize industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine. Teich will receive the award in Boston on November 20, 2015, during SFRBM 2015, the premier event for cutting-edge research in all aspects of redox biology. Seahorse was acquired by Agilent Technologies on Nov. 1; Teich is now general manager of the Seahorse team at Agilent.
“Led by Jay, Seahorse Bioscience has been an industry leader for many years, developing innovative technologies so many others strive to achieve,” said SFRBM president Neil Hogg, Ph.D. “We are thrilled to recognize this achievement and look forward to seeing the next chapter of scientific breakthroughs as Seahorse becomes a part of Agilent.”
Seahorse Bioscience's unique technology is the perfect complement to Agilent's market-leading separations and mass spectrometry solutions. The combination of these two platforms will give scientists a more comprehensive and faster path to researching the most challenging diseases affecting humankind, including a greater understanding of redox biology, the study of electron flow through biological circuits, sensors, and switches, applicable in many areas critical to human health including cancer, heart disease, aging, cardiovascular disease and obesity.
“I am honored to receive the SFRBM CEO Innovator Award on behalf of my colleagues at Seahorse Bioscience,” said Teich. “We are committed to developing instruments and assay kits for measuring cell metabolism, tools that provide scientists a better understanding of mitochondrial function and disease.”
Founded in 1987, the Society for Redox Biology and Medicine (http://sfrbm.org) is an international organization of 1,200 scientists, investigators and clinicians who conduct research in the area of redox biology. These areas have shown explosive growth over the last decade and are now integral to major initiatives in basic, applied and translational research, including development of new therapies in cancer, heart disease, aging and cardiovascular disease.
About Seahorse Bioscience, a Part of Agilent Technologies
Seahorse Bioscience XF metabolic analyzers and stress test kits are the industry standard in cell metabolism measurements. Scientists worldwide are using Seahorse technology to advance their research in understanding the role of cell metabolism. Seahorse is headquartered in Billerica, Massachusetts, U.S., and has regional offices in Copenhagen, Denmark, and Shanghai, China. For more information, visit www.seahorsebio.com. Agilent Technologies Inc., a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.0 billion in fiscal 2014 and employs about 12,000 people worldwide. Agilent marks its 50th anniversary in analytical instrumentation this year. For more information, visit www.agilent.com.
On October 21-22, SFRBM leadership held 12 meetings on Capitol Hill in Washington D.C. to introduce key Congressional offices to the society and discuss important issues impacting members, including increased NIH funding, diversity and public engagement in science.
SFRBM met with senior staff of the Senate Committee on Health, Education, Labor and Pension (HELP), which has jurisdiction encompassing most of the agencies, institutes, and programs of the Department of Health and Human Services including the NIH. SFRBM also met directly with Senator Chuck Grassley, Senator Joni Ernst, Congressman Dave Loebsack to name a few. One goal of these meetings was to build relationships between key Congressional offices and SFRBM. While SFRBM is a member of the Federation of American Society for Experimental Biology (FASEB), which does an amazing job raising awareness of legislation impacting the scientific community, they do not promote or raise awareness about SFRBM specifically.
SFRBM leaders and staff who participated included Neil Hogg, Rick Domann, Sruti Shiva, Eric Kelley, Kent Lindeman and Brent Carney, the society’s communications and public affairs partner.
In talking to members of Congress about ways to increase NIH research funding, there was pledged support for this initiative, however no real solutions laid out for how to fund it. Congressmen James Sensenbrenner’s office indicated they would not vote in favor of any NIH bill that did not clearly identify the funding source. Senator Robert Casey’s office stated that the pharmaceutical industry, who benefits greatly from the bench science resulting from NIH funding, doesn’t seem to prioritize the importance of NIH funding to support this research when they are speaking with legislators.
After meeting with the Senate HELP Committee, we came away with guarded optimism. The Committee is currently working on an “Innovation Bill” that will be the Senate companion to the 21st Century Cures Act which passed the House earlier this year. This bill will focus on three sectors, NIH research, FDA research and Health IT. While the bill is set to be introduced in the next couple weeks, making our visit extremely timely, it is unclear if it will contain increased funding for the NIH. Senator Patty Murray, in her role as Committee Ranking Member, indicated to us that such funding is a “must have” in the legislation.
Overall, we were thrilled with the reception we received and the opportunity this gives us in the coming years. Given the timing of the legislation in the HELP Committee and the FY2016 budget, our visit couldn’t have come at a more pivotal time. As one of the benefits you receive as a SFRBM member, we feel this representation in Washington was extremely beneficial for our organization, its members and the issues so many of us hold dear. We look forward to continuing to build the relationships that were started in DC last week, to the benefit SFRBM members in future years.
Neil Hogg, Ph.D.
Medical College of Wisconsin
Category: Redox Biology
To Experienced Mentors,
My principal investigator (PI) helped me with my writing, the postdocs in lab taught me bench science, and my fellow grad students helped me better communicate my science. I’m going to be in charge of training an undergrad on a project which will be an extension of my dissertation work. I’m excited, and my PI thinks I am ready for this responsibility, but I don’t know if I am going to be good at training as this is my first time as a science mentor. Should I be worried?
A Nervous New Mentor
Dear A Nervous New Mentor,
First off, congratulations on taking this leadership role in your lab. Training freshmen scientists is one of the most important steps in maintaining the success of not only individual research programs, but scientific progress in general. That being said, training a new lab member as a graduate student or even a postdoc for the first few times can be challenging because rarely will you have someone providing constructive criticism as you employ your own method of training.
Even though this is your first time in a training position, know that your PI trusts you at this point in your career to be able to handle this responsibility. This is not to say there won’t be speed bumps and some additional demands on your already busy lifestyle. But that is where you can utilize your mentors’ help. Never be afraid to ask for advice from your PI and other colleagues who have had the opportunity to train new lab members. Use their advice to mold your own personal training strategy, and over time with trial and error you can improve your mentoring strategy. Even seasoned investigators sometimes have to modify the way they teach based on the available resources and personal characteristics of the trainee.
So to answer your question, don’t be worried. Instead, utilize your skills as a scientist to be observant and know that some hardships and failures may come up that you will have to find solutions to implement.
An Experienced Mentor (who is still learning a few tricks)
DOT: Tell us about your background and current passion in your professional life?
My father was an experimental physicist and I remember watching him assemble a hand blown glass vacuum apparatus to test the hypothesis that led to his graduate degree from the University of Vermont. My own first hands-on laboratory experience outside a classroom was at Argonne National Laboratory where I worked with Dr. Thomas M. Seed on low dose-rate gamma radiation-induced granulocytic leukemia in canines. This led to an interest in radiation biology and cancer and my matriculation to the University of Wisconsin-Madison where I performed graduate studies in the Human Oncology department under the mentorship of Dr. Kelly H. Clifton. My graduate training was in classical cellular radiation biology and carcinogenesis with a strong emphasis on organismal physiology and endocrinology. Since ~70% of the biological effects of gamma and x-ray irradiation are mediated through the radiolysis of water to generate oxygen free radicals, a natural interest in free radical processes in biology and medicine was forged from this background. I furthered my training at the post-doctoral level pursuing studies in molecular biology, carcinogenesis and redox-signaling at the University of Arizona Cancer Center in the laboratory of Dr. G. Tim Bowden. In 1993 I joined the University of Iowa and was fortunate to work as a colleague of Dr. Larry W. Oberley for 15 years until his untimely death in 2008. His inspiration helped crystalize for me a vision for how cellular redox metabolism communicates with epigenetic writer and eraser enzymes which when perturbed lead to aberrant epigenetic marks observed in tumor cells. I have pursued this general concept and many other side projects during my 23 year tenure at The University of Iowa. The current passion in my professional life is to watch the professional and career development of my numerous trainees from over the years unfold as they become successful in their own independent research careers and carry the torch of knowledge forward to the next generation.
Rick Domann, Ph.D.
DOT: Briefly describe your research interest and what is the most notable research achievement from your lab?
My research interests are in redox signaling, metabolism, cancer and epigenetics. I seek to understand how long-term perturbations to normal redox homeostasis such as those that occur in pathologies are drivers of an altered epigenetic landscape that changes phenotype without changing genotype. The most notable achievement from our lab has been the discovery that unfolded over the last five years which is that the SOD3 gene that encodes the extracellular superoxide dismutase is a potent metastasis suppressor gene and that its loss in several human epithelial cancers causes an acceleration of disease progression and a decrease in metastasis-free survival. This is in part due to the potent anti-inflammatory effects of EcSOD; its absence allows the proliferation of free radical reactions that degrade and destroy sensitive ECM components and accelerate invasion and metastasis.
DOT: Who has been your greatest teacher? What do you think the most important factors that shaped your career?
This is a difficult question to answer because there were and still are several very important mentors in my life, and it is nearly impossible to select the ONE that has had the most influence. I’d have to say that looking back at the direction of my work and the publications resulting over the last 30 years that my most influential teachers and mentors were Kelly Clifton and Larry Oberley.
DOT: In the current climate in which investigators are faced with decreased NIH funding for research and low morale, what is the best advice?
There is always room for optimism, and recent reports are that NIH may get a long-needed boost in support from Congress. Newt Gingrich recently wrote an Op-Ed in the New York Times (Apr 21, 2015) calling for another doubling of the NIH budget, and in mid-May the U.S. House of Representatives released a draft bill that aims to increase the NIH budget by $10 billion over 5 years. These shifting winds mean that investigators should stay tuned for additional evolving opportunities. Your Society leadership is trying to bring awareness to the field of redox biology and medicine at the NIH and other federal granting agencies by bringing scientific review administrators and program officers to the annual meetings to hold workshops for our members and highlight recent trends and funding opportunities in our field.
DOT: Being a mentor, you have shaped many students (graduate and postdoc) to enter academic and industry research, any tips how to shape individuals for these scientific fields?
There is no substitute for assiduity and a solid work ethic; being present is the greatest part of success. Beyond that, astute observational and critical thinking skills are required in a scientific profession of any kind. In addition, organizational, time management, and effective interpersonal communication are all key elements to success in science. I believe that proposals and reports need be compiled in a technically accurate manner and written in cogent prose in both academic and industry roles, so I think at least at the graduate training level there is little difference in how I would prepare them. At the post-doctoral level, a postdoc interested in industry may test the waters first by doing an industry post-doc or internship.
DOT: What do you think is the direction the Oxidative Stress field is heading?
Interesting question… I think that life is stress, especially life in an oxygen rich world. Thus all living organisms are in a non-steady state equilibrium that oscillates around various levels depending upon physical, biological, and environmental cues. A normal state of existence might be thought of as “eustress”, which is a normal and good part of life that is hormetic and that allows for rapid adaptive responses in either direction to maintain cell and tissue redox balance. Additionally, there is finally a realization in the community that redox sensors have been frequently misconstrued as antioxidant defenses when in many cases they are in fact signal transducing modules. All major disease of mankind possess an oxidative stress component to their pathologies, and so in order to cure these disease a deeper understanding of the redox signaling relays evolved in life in oxygen is needed.
DOT: And in the other direction, translational research.
Translational research utilizing basic knowledge learned from redox biology is growing exponentially. The role of free radicals and redox biology in inflammation, cancer, diabetes, cardiovascular and pulmonary diseases is well appreciated. Now, pharmacological control of certain of these systems is well in hand and drugs that mimic SOD activity are in clinical trials. Also, the paradoxical pro-oxidant effects of high dose vitamin C are making a big comeback in cancer clinics nationally with promising results using high C as an adjuvant for traditional therapies with no notable toxicity. Also, the role of redox couples that sense and signal oxidative stress, such as NADH/NAD+ are found to be vitally important for aging and cancer by altering the activity of sirtuin family enzymes, and oral nicotinamide was recently found to provide significant protection from non-melanoma skin cancer in high risk people. These are just a few examples of a growing list of medical applications forged from the furnace of free radical biology.
DOT: How has science/research changed during your life as a scientist?
I finished my BS in Biology in 1983, started grad school in 1984, and PCR was invented in 1985. That single method revolutionized experimental biology. In 1998 endothelial-derived relaxing factor was discovered to be nitric oxide which led to the Nobel Prize for scientists working in the field of free radical biology. I’ve always thought it was curious that the work on NO led to a prize, but the discovery of superoxide in biological tissues by Fridovich and McCord didn’t, especially since this was the seminal finding that gave birth to the field of free radical biology. The human genome initiative was completed by 2003; before that the GenBank was a fairly primitive and barely searchable database. The complete sequencing of many human genomes and the associated browser capability to navigate the human genome has changed everything about the future of medicine. Through that process, advances in DNA sequencing technology and speed have exceeded all expectations and has improved faster than Moore’s law. This is enabling an unprecedented examination of human microbiomes, genetic heterogeneity of cancer, even identifying heritable disease genes of embryos in utero from non-invasive blood tests of the mother. Finally, and directly relevant to mitochondrial redox biology, the United Kingdom recently approved the “three-parent baby”, which is aimed at eradicating familial mitochondrial diseases.
DOT: How important is the SFRBM conference to you and your trainees? Being elected as the president, what are the ideas are you planning for this society?
The annual SFRBM meeting has always been an extremely important meeting for me and my trainees. I have attended every meeting but one since 1994 and have usually travelled with a small entourage of trainees. The annual meeting has been important to me because it has allowed me to showcase my lab’s work in a receptive and like-minded audience. My trainees have been frequently selected for talks and awards and have benefited enormously from their sustained involvement in the Society. The Society is at a crossroads now, many members believe that it is time to re-brand and become more inclusive of all redox biology rather than exclusive to free radicals. Membership has been declining over the last few years and it is time to reinvigorate and re-energize the Society with an infusion of fresh blood that can most effectively be accomplished by broadening the scope and appeal of the Society to a wider scientific audience, one that would encompass and embrace all relevant redox biology in pathology and medicine. I have met personally with members of the membership committees and they are working with me on proactive strategies to not only retain existing members but also to recruit new members from all possible avenues. I believe that our new membership in FASEB will help in this regard, but also our Society would benefit from becoming more proactive at recruiting new members from like-minded scientists in other professional societies.
DOT: What are your hobbies outside the laboratory?
I enjoy reading, music, cooking, biking, traveling, hiking, fishing, & downhill skiing. I walk my dogs daily and always strive for at least ten thousand steps per day on the pedometer!
Category: SfRBM Member Profile
Most of the SOD mimics thus far developed belong to the classes of Mn-(MnPs) and Fe porphyrins(FePs), Mn(III) salens, Mn(II) cyclic polyamines and metal salts. Due to their remarkable stability we have predominantly explored Mn porphyrins, aiming initially at mimicking kinetics and thermodynamics of the catalysis of O2− dismutation by SOD enzymes. Several MnPs are of potency similar to SOD enzymes. The in vivo bioavailability and toxicity of MnPs have been addressed also.
Numerous in vitro and in vivo studies indicate their impressive therapeutic efficacy. Increasing insight into complex cellular redox biology has been accompanied by increasing awareness of complex redox chemistry of MnPs. During O2− dismutation process, the most powerfulMn porphyrin-based SOD mimics reduce and oxidize O2− with close to identical rate constants. MnPs reduce and oxidize other reactive species also (none of them specific to MnPs), acting as reductants (antioxidant) and pro-oxidants.
Distinction must be made between the type of reactions of MnPs and the favorable therapeutic effects we observe; the latter may be of either anti- or pro-oxidative nature. H2O2/MnP mediated oxidation of protein thiols and its impact on cellular transcription seems to dominate redox biology of MnPs. It has been thus far demonstrated that the ability of MnPs to catalyze O2−dismutation parallels all other reactivities (such as ONOO− reduction) and in turn their therapeutic efficacies.
Assuming that all diseases have in common the perturbation of cellular redox environment, developing SOD mimics still seems to be the appropriate strategy for the design of potent redox-active therapeutics.